MARKET

CELG-RT

CELG-RT

Celgene
NYSE

Real-time Quotes | Nasdaq Last Sale

0.6231
+0.0220
+3.66%
Opening 09:32 02/26 EST
OPEN
0.6231
PREV CLOSE
0.6011
HIGH
0.6231
LOW
0.6231
VOLUME
2.00K
TURNOVER
--
52 WEEK HIGH
1.650
52 WEEK LOW
0.3541
MARKET CAP
443.27M
P/E (TTM)
0.0777
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of CELG-RT and other stocks commission-free!

Open a Webull account and fund it to get a free stock

CELG-RT News

More
  • Bristol-Myers Placed A Big Bet On Celgene�s Pipeline. Will It Pay Off For Investors?
  • MotleyFool.com · 12/16/2019 14:55
  • Better Buy: Gilead Sciences vs. Amgen
  • MotleyFool.com · 12/15/2019 14:00
  • Here's Why You Should Own Amgen Stock in 2020
  • MotleyFool.com · 12/12/2019 15:38
  • Here�s Why bluebird bio Shares Jumped Almost 12% Today
  • MotleyFool.com · 12/10/2019 21:31

Industry

Pharmaceuticals
+0.83%
Pharmaceuticals & Medical Research
+0.98%

Hot Stocks

Symbol
Price
%Change
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%

About CELG-RT

Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation. Its commercial-stage products include REVLIMID (lenalidomide), POMALYST/IMNOVID (pomalidomide), OTEZLA (apremilast), ABRAXANE (paclitaxel albumin-bound particles for injectable suspension), VIDAZA, azacitidine for injection (generic version of VIDAZA) and THALOMID (thalidomide). Its clinical trial activity includes trials across the disease areas of hematology, solid tumors, and inflammation and immunology. The Company also markets ISTODAX, which is an epigenetic modifier. The Company is also evaluating AG-221 (enasidenib) in combination with VIDAZA in newly diagnosed acute myeloid leukemia with isocitrate dehydrogenase-2 mutations.
More

Webull offers kinds of Celgene Corporation stock information, including NYSE:CELG RT real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CELG RT stock news, and many more online research tools to help you make informed decisions.